Browsing Tag
diabetic macular edema
12 posts
Why Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) just strengthened the Eylea HD case against Roche’s Vabysmo
Regeneron won FDA approval for every-20-week Eylea HD dosing in wet AMD and DME. Read what it means for Regeneron, rivals, and retinal drug markets.
A new Vabysmo challenger? Innovent Biologics’ IBI324 just made the retinal drug race more interesting
Innovent Biologics is advancing IBI324 into Phase 3 after new retinal disease data versus Vabysmo. Read what it could mean for ophthalmology now.
Vabysmo shows 4-year durability in wet AMD and 60% lesion clearance in PCV: What the new Genentech data reveals
Genentech’s Vabysmo shows four years of vision durability in AMD and strong lesion control in PCV—see what’s next for this bispecific breakthrough.
Innovent Biologics advances Phase 2 study of efdamrofusp alfa in diabetic macular edema amid global push for longer-acting therapies
Innovent launches Phase 2 trial of its anti-VEGF-complement fusion protein IBI302 to rival Faricimab in treating diabetic macular edema.
4D Molecular Therapeutics strengthens cash position, eyes Phase 3 success for 4D-150
4D Molecular Therapeutics (4DMT) has announced its full-year 2024 financial results, highlighting key advancements in its late-stage clinical…
Breakthrough in diabetes care: Roche’s Susvimo could revolutionize eye treatment
Roche, a global leader in pharmaceuticals and diagnostics, recently unveiled two-year data from the pivotal Phase III Pagoda…
FDA approves Roche’s Vabysmo prefilled syringe for eye diseases, expanding treatment options for millions
Roche (SIX: RO, ROG; OTCQX: RHHBY), a global leader in pharmaceuticals and diagnostics, announced a significant advancement in…
FDA approves Genentech’s Vabysmo prefilled syringe for eye diseases
In a significant advancement in the treatment of eye diseases, the U.S. Food and Drug Administration (FDA) has…
Rezolute’s Phase 2 trial of RZ402 shows significant CST reduction in DME patients
Rezolute, Inc. (Nasdaq: RZLT), a leader in the development of novel therapies for serious metabolic and rare diseases,…
KSI-301 phase 1b trial : Kodiak Sciences reports new safety, efficacy, and durability data
KSI-301 phase 1b trial : Kodiak Sciences said that its ongoing phase 1b clinical trial of its intravitreal…